Metagenomi Therapeutics, Inc.
MGXNasdaq
$1.24
0.0%Jul 17 close · end-of-day
Price
1Y↓ -41.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$46.6M
Enterprise Value
-$93.6M
P/E
—
P/S
2.1
P/B
0.3
EV/EBITDA
—
PEG
—
FCF Yield
-187.8%
Dividend Yield
—
Revenue (TTM)
$22.3M
Net Income (TTM)
-$85.9M
Free Cash Flow (TTM)
-$87.5M
Gross Margin
—
Operating Margin
-415.5%
Net Margin
-384.6%
ROE
-62.3%
ROIC
—
Debt / Equity
—
Net Cash
$140.2M
Return 1Y
-41.8%
Company profile
We are a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. Our principal executive offices are located 5959 Horton Street, 7th Floor, Emeryville, California.
- CEO
- Brian C. Thomas
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- metagenomi.co
Management & directors
- Irish JianChief Executive Officer
- Wapnick PamelaChief Financial Officer
- Wein MatthewSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
MGX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.2M↓ -69.8%
Diluted EPS-$0.61↓ -10.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $44.8M | $52.3M | $25.2M |
| Gross profit | — | — | — |
| Operating income | -$78.5M | -$88.9M | -$96.0M |
| Net income | -$68.3M | -$78.1M | -$87.9M |
| Diluted EPS | -$20.05 | -$2.36 | -$2.36 |
| Operating cash flow | -$91.4M | -$109.1M | -$88.9M |
| Free cash flow | -$101.2M | -$112.2M | -$89.5M |
| Gross margin | — | — | — |
| Operating margin | -175.4% | -170.0% | -380.9% |
| Net margin | -152.5% | -149.3% | -348.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.0M | $11.5M | $9.6M | $4.1M | $8.5M | $8.7M | $3.9M | $1.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$16.9M | -$22.4M | -$20.6M | -$27.8M | -$21.0M | -$22.8M | -$24.4M | -$24.6M |
| Net income | -$10.7M | -$18.8M | -$23.4M | -$25.0M | -$19.9M | -$20.4M | -$22.5M | -$23.1M |
| Diluted EPS | -$0.29 | -$0.51 | -$0.37 | -$0.68 | -$0.54 | -$0.55 | -$0.59 | -$0.61 |
| Operating cash flow | -$26.3M | -$26.6M | -$26.3M | -$22.8M | -$21.3M | -$21.3M | -$23.5M | -$21.2M |
| Free cash flow | -$27.0M | -$27.8M | -$26.6M | -$23.1M | -$21.4M | -$21.3M | -$23.6M | -$21.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -84.3% | -194.4% | -214.5% | -674.1% | -246.5% | -263.8% | -623.0% | -1970.1% |
| Net margin | -53.7% | -163.0% | -243.4% | -606.7% | -233.9% | -235.5% | -576.0% | -1847.7% |
Company news
May 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-05 | Irish Jian· See Remarks | Sale | 3,737 | $1.30 | $4,854.36 | filing |
| 2026-06-05 | Wapnick Pamela· Chief Financial Officer | Sale | 2,884 | $1.30 | $3,746.32 | filing |
| 2026-06-05 | Wein Matthew· See Remarks | Sale | 558 | $1.30 | $724.84 | filing |
| 2026-04-01 | Irish Jian· See Remarks | Award | 46,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | Wein Matthew· See Remarks | Award | 11,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | Wapnick Pamela· Chief Financial Officer | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-03-05 | Irish Jian· Chief Executive Officer | Sale | 1,607 | $1.60 | $2,571.20 | filing |
| 2026-03-05 | Wapnick Pamela· Chief Financial Officer | Sale | 1,581 | $1.60 | $2,529.60 | filing |
| 2026-03-05 | Wein Matthew· See Remarks | Sale | 482 | $1.60 | $771.20 | filing |
| 2025-12-05 | Thomas Brian C. | Sale | 3,830 | $1.77 | $6,786.38 | filing |
| 2025-12-05 | Irish Jian· Chief Executive Officer | Sale | 1,602 | $1.77 | $2,838.58 | filing |
| 2025-12-05 | Wapnick Pamela· Chief Financial Officer | Sale | 1,576 | $1.77 | $2,792.51 | filing |
| 2025-12-05 | Wein Matthew· See Remarks | Sale | 199 | $1.77 | $352.61 | filing |
| 2025-12-05 | Irish Jian· Chief Executive Officer | Gift | 228,462 | $0.00 | $0.00 | filing |
| 2025-12-01 | Irish Jian· Chief Executive Officer | Award | 211,000 | $1.60 | $337,600.00 | filing |
| 2025-12-01 | Wapnick Pamela· Chief Financial Officer | Award | 120,000 | $1.60 | $192,000.00 | filing |
| 2025-12-01 | Wein Matthew· See Remarks | Award | 96,000 | $1.60 | $153,600.00 | filing |
| 2025-12-01 | Irish Jian· Chief Executive Officer | Award | 37,500 | $1.60 | $60,000.00 | filing |
| 2025-09-05 | Thomas Brian C. | Sale | 2,701 | $1.81 | $4,888.81 | filing |
| 2025-09-05 | Irish Jian· Chief Executive Officer | Sale | 1,602 | $1.81 | $2,899.62 | filing |
| 2025-09-05 | Wapnick Pamela· Chief Financial Officer | Sale | 1,576 | $1.81 | $2,852.56 | filing |
| 2025-09-05 | Wein Matthew· See Remarks | Sale | 199 | $1.81 | $360.19 | filing |
Latest 22 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.